Kisspeptin receptor agonist (FTM080) increased plasma concentrations of luteinizing hormone in anestrous ewes.

Whitlock BK, Daniel JA, Amelse LL, Tanco VM, Chameroy KA, Schrick FN

PeerJ5 Nov 2015Cited by 14 (Europe PMC)

PMID26587345PMCIDPMC4647575DOI10.7717/peerj.1382PepBankPUB-26587345

Summary

Kisspeptin receptor (KISS1R) agonists with increased half-life and similar efficacy to kisspeptin in vitro may provide beneficial applications in breeding management of many species. However, many of these agonists have not been tested in vivo. These studies were designed to test and compare the effects of a KISS1R agonist (FTM080) and kisspeptin on luteinizing hormone (LH) in vivo. In experiment 1 (pilot study), sheep were treated with FTM080 (500 pmol/kg BW) or sterile water (VEH) intravenosuly. Blood was collected every 15 min before (1 h) and after (1 h) treatment. In experiment 2, sheep were treated with KP-10 (human Metastin 45-54; 500 pmol/kg BW), one of three dosages of FTM080 (500 (FTM080:500), 2500 (FTM080:2500), or 5000 (FTM080:5000) pmol/kg BW), or VEH intravenously. Blood was collected every 15 min before (1 h) and after (4 h) treatment. In experiment 1, FTM080:500 increased (P < 0.05) plasma LH concentrations when compared to VEH. The area under the curve (AUC) of LH following FTM080:500 treatment was also increased (P < 0.05). In experiment 2, plasma LH concentrations increased (P < 0.05) following treatment with KP-10 and FTM080:5000 when compared to VEH and FTM080:500. The AUC of LH following KP-10 was greater than (P < 0.05) all other treatments and the AUC of LH following FTM080:5000 was greater than (P < 0.05) all treatments except KP-10. These data provide evidence to suggest that FTM080 stimulates the gonadotropic axis of ruminants in vivo. Any increased half-life and comparable efficacy of FTM080 to KP-10 in vitro does not appear to translate to in vivo in sheep.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In sheep, intravenous kisspeptin‑10 increased plasma luteinizing hormone concentrations compared with vehicle.
In plain wordsIn sheep, kisspeptin‑10 raised blood luteinizing hormone more than vehicle did.
Peptide
Kisspeptin-10
Outcome
IncreasePlasma LH concentration versus vehicle
Study
sheepn: not reported in source
anestrous ewes
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
500 pmol/kg BW · intravenousAs given in this study (sheep).
Source sentences
Summary
In experiment 2, plasma LH concentrations increased (P < 0.05) following treatment with KP-10 and FTM080:5000 when compared to VEH and FTM080:500.
1 context sentence(design, population, supporting numbers)
Summary · context
In experiment 2, sheep were treated with KP-10 (human Metastin 45-54; 500 pmol/kg BW), one of three dosages of FTM080 (500 (FTM080:500), 2500 (FTM080:2500), or 5000 (FTM080:5000) pmol/kg BW), or VEH intravenously.
Show in the study text Report a problemFND-2658734501
02AnimalAnimal study (in vivo)Efficacy outcome
In sheep, intravenous kisspeptin‑10 increased plasma luteinizing hormone concentrations compared with the low dose of the agonist FTM080 (500 pmol/kg).
In plain wordsIn sheep, kisspeptin‑10 raised blood luteinizing hormone more than a low dose of the agonist FTM080.
Peptide
Kisspeptin-10
Outcome
IncreasePlasma LH concentration versus FTM080 500 pmol/kg
Study
sheepn: not reported in source
anestrous ewes
Comparator
FTM080 500 pmol/kg BW
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
500 pmol/kg BW · intravenousAs given in this study (sheep).
Source sentences
Summary
In experiment 2, plasma LH concentrations increased (P < 0.05) following treatment with KP-10 and FTM080:5000 when compared to VEH and FTM080:500.
1 context sentence(design, population, supporting numbers)
Summary · context
In experiment 2, sheep were treated with KP-10 (human Metastin 45-54; 500 pmol/kg BW), one of three dosages of FTM080 (500 (FTM080:500), 2500 (FTM080:2500), or 5000 (FTM080:5000) pmol/kg BW), or VEH intravenously.
Show in the study text Report a problemFND-2658734502
03AnimalAnimal study (in vivo)Efficacy outcome
In sheep, the area under the curve of luteinizing hormone after kisspeptin‑10 was greater than after all other treatments, including vehicle and all FTM080 doses.
In plain wordsIn sheep, kisspeptin‑10 gave a larger total luteinizing hormone rise than vehicle or any dose of the agonist FTM080.
Peptide
Kisspeptin-10
Outcome
IncreaseLH area under the curve
Study
sheepn: not reported in source
anestrous ewes
Comparator
Vehicle and all FTM080 doses
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
500 pmol/kg BW · intravenousAs given in this study (sheep).
Source sentences
Summary
The AUC of LH following KP-10 was greater than (P < 0.05) all other treatments and the AUC of LH following FTM080:5000 was greater than (P < 0.05) all treatments except KP-10.
1 context sentence(design, population, supporting numbers)
Summary · context
In experiment 2, sheep were treated with KP-10 (human Metastin 45-54; 500 pmol/kg BW), one of three dosages of FTM080 (500 (FTM080:500), 2500 (FTM080:2500), or 5000 (FTM080:5000) pmol/kg BW), or VEH intravenously.
Show in the study text Report a problemFND-2658734503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.